CUT umbilical cord milking to prevent Encephalopathy in infants with prenatal drug exposure

Dr Ju Lee Oei0 个研究点目标入组 96 人开始时间: 2024年8月6日最近更新: 2024年8月12日

适应症

试验速览

暂无简介。

•Opioid-using mothers-
•1) 18-35 yrs, healthy weight (BMI 25-29.9; Australian Institute of Health and Welfare, 2023)
•2) Singleton pregnancy
•3) Willingness and ability to give written informed consent prior to birth
•4) Willingness to participate in and comply with the study
•5) Use of opiates (heroin, methadone, buprenorphine, codeine, oxycodone, fentanyl, tramadol, pethidine) during pregnancy as confirmed via self-report and/or maternal and neonatal urine toxicology
•Non opioid-using mothers-
•1-4 as above
•5) No use of substances (e.g. opiates) during pregnancy as confirmed via self-report and/or maternal and neonatal urine toxicology
•1) Born at >39-41 weeks of gestation (or, if gestation unknown, an estimated birthweight of greater than or equal to 2.5 kg)

•HIV positive status, diabetes
•Complications with pregnancy (e.g. gestational diabetes, pre-eclampsia, chorioamnionitis)
•Chromosomal, inflammatory or autoimmune disorders with or without medication
•Use of any anti-inflammatory or steroid medications
•Consent unable to be obtained before birth (e.g., insufficient time, precipitous labour, cognitive impairment, inebriation)
•Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study
•Non-vigorous status at birth
•Major congenital or chromosomal anomalies
•Auto-immune or infectious diseases
•Admission to NICU or requiring ventilatory support

发起方

Dr Ju Lee Oei